The Effect of Live Attenuated Inactivated Influenza Vaccine on Experimental Human Pneumococcal Carriage Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

324 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2017-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators are interested in examining the effect of the Live Attenuated Influenza (flu) Vaccine (LAIV) upon nasal carriage of bacteria called Streptococcus pneumoniae (also known as pneumococcus). The nasal spray is a live attenuated vaccine which means that it has weakened virus that does not cause disease. This vaccine is licenced in the United Kingdom for children and adolescents from 2 to 18 years of age.

Pneumococcus can commonly be found harmlessly inhabiting the nose where it does not cause any problem (pneumococcal colonisation). About 10% of adults carry pneumococcus at any one time, and almost all adults experience an episode of carriage at least once per year. Carriage acts as a natural vaccine, boosting immunity against pneumococcal infection in adults and children.

During influenza there is an increase in the burden of pneumococcal pneumonia. We have studied the effects of pneumococcus for many years and have developed a programme in which we can nasally inoculate healthy participants with a dose of pneumococcus and achieve a reproducible carriage rate. The investigators would now like to use this model to investigate the effects of the nasal influenza vaccine upon pneumococcal carriage and to better understand how influenza infections lead to increased susceptibility to pneumonia.

Pneumococcal disease in young adults is rare - less than 10 cases per 100,000 people per year. When pneumococcus does cause problems, usually in young children or elderly people, it can be very serious as it is responsible for diseases such as pneumonia, sepsis and meningitis, which kill millions of children around the world each year.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination

NCT07133802

Prevention of Influenza

NOT_YET_RECRUITING PHASE3

A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia

NCT02972957

Influenza

COMPLETED PHASE4

Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus

NCT02950688

Influenza, Human

WITHDRAWN PHASE1

A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)

NCT02964065

Influenza

COMPLETED PHASE3

The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine

NCT05056519

Influenza Prevention

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Secondary bacterial infections such as pneumococcal pneumonia are a leading cause of death during influenza endemics. Individuals recently infected with influenza become more susceptible to pneumonia, an effect associated with increased density of pneumococcal carriage in the nose and uncontrolled inflammatory immunological responses. The interaction of influenza virus and pneumococcus has been known and well documented. Recent works have shown that the Live Attenuated Influenza Vaccine (LAIV) enhances pneumococcal carriage in murine models. These results highlighted the potential effect of mass immunization of children with LAIV on pneumococcal carriage. Increased carriage could lead to increased pneumococcal disease in LAIV-vaccinated individuals as well as increased bacterial transmission within the population. LAIV has been licensed for use in children since 2011 in Europe, and has been increasingly administered in children and adults in the USA. There is an urgent need for a clinical trial that will determine the effect of LAIV on pneumococcal carriage dynamics.

The investigators have developed a safe and reproducible experimental human pneumococcal carriage (EHPC) model. The investigators will use EHPC to define the effect of antecedent and concurrent LAIV on pneumococcal carriage acquisition, density and duration. The investigators will perform two double - blinded Randomised Controlled Trials (RCT) to compare LAIV with Quadrivalent Inactivated Influenza Vaccine (QIV). The investigators will compare clinical symptoms, pneumococcal carriage density and duration associated with both vaccines administered antecedent to or concurrently with EHPC inoculation. Changes in the nasopharyngeal microbiome, inflammatory responses in the nasal mucosal and lung cellular immunity associated with influenza virus and pneumococcus interaction will be investigated. This project may provide some reassurance regarding the impact of mass immunization with LAIV on carriage or, if carriage is increased, will provide knowledge of how a natural carriage episode might develop into pneumonia in susceptible subjects during pandemic influenza.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumonia Influenza, Human

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

DBRCT performed as two studies over two flu seasons. 2 arms to each study.

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

DOUBLE

Participants Investigators

Physical blind folds worn by participant. Unblinded research nurses to deliver the vaccines

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study One: LAIV + Inoculation

LAIV Nasal Spray: Inoculation (FLUMIST or FLUENZ) plus intramuscular placebo then inoculation with pneumococci bacteria

Group Type ACTIVE_COMPARATOR

Study one: LAIV + Inoculation

Intervention Type BIOLOGICAL

Pneumococci bacteria nasal inoculation following vaccination with LAIV and intramuscular placebo

Study One: Placebo + inoculation

Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo then inoculation with pneumococci bacterial

Group Type PLACEBO_COMPARATOR

Study one: Placebo + Inoculation

Intervention Type BIOLOGICAL

Pneumococci bacteria nasal inoculation following vaccination QIV with nasal placebo spray

Study Two: Inoculation + LAIV

Inoculation with pneumococci bacteria then Live attenuated Influenza Vaccine Nasal Spray (FLUMIST or FLUENZ) plus intramuscular placebo

Group Type ACTIVE_COMPARATOR

Study two: Inoculation + LAIV

Intervention Type BIOLOGICAL

Pneumococci bacteria nasal inoculation prior to vaccination with LAIV and intramuscular placebo

Study Two: Inoculation + placebo

Inoculation with pneumococci bacteria then Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo

Group Type PLACEBO_COMPARATOR

Study two: Inoculation + placebo

Intervention Type BIOLOGICAL

Pneumococci bacteria nasal inoculation prior to vaccination QIV with nasal placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Study one: LAIV + Inoculation

Pneumococci bacteria nasal inoculation following vaccination with LAIV and intramuscular placebo

Intervention Type BIOLOGICAL

Study one: Placebo + Inoculation

Pneumococci bacteria nasal inoculation following vaccination QIV with nasal placebo spray

Intervention Type BIOLOGICAL

Study two: Inoculation + LAIV

Pneumococci bacteria nasal inoculation prior to vaccination with LAIV and intramuscular placebo

Intervention Type BIOLOGICAL

Study two: Inoculation + placebo

Pneumococci bacteria nasal inoculation prior to vaccination QIV with nasal placebo

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FLUMIST or FLUENZ AstraZeneca Fluarix Tetra GlaxoSmithKline FLUMIST or FLUENZ AstraZeneca Fluarix Tetra GlaxoSmithKline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* have capacity to give informed consent
* aged 18-50 yrs - ages chosen to minimise the risk of pneumococcal infection
* speak fluent English- to ensure a comprehensive understanding of the research project and their proposed involvement, in order to minimise any communication issues to maximise participant safety.

Exclusion Criteria

* currently involved in another study unless observational or in follow-up phase (non-interventional)
* received any influenza vaccine in the last 2 years

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes